智慧医疗

订阅

MedSci主页 / 所有栏目 / 智慧医疗

Clinica Chimica Acta：新型PHI诺模图的开发和内部验证以识别侵袭性前列腺癌

2020-03-19 MedSci原创 MedSci原创

侵袭性前列腺癌
关注

前列腺健康指数(PHI)是一种新的前列腺癌(PCa)检测方法，提高了总PSA (tPSA)的表现，并与肿瘤的侵袭性有关。本研究目的是在包含PHI的多变量模型的基础上构建诺模列线图。

前列腺健康指数(PHI)是一种新的前列腺癌(PCa)检测方法，提高了总PSA (tPSA)的表现，并与肿瘤的侵袭性有关。本研究目的是在包含PHI的多变量模型的基础上构建诺模列线图，以估计侵袭性PCa的个体可能性。

研究人员选择了276名活检对象，其中包括151名PCa患者。采用D 'Amico标准将这些患者分为三组，这三组与进展风险相关。将中度和高危PCa认为是侵袭性PCa。利用实验室(tPSA、%fPSA、%p2PSA、PHI)和临床变量建立了预测侵袭性PCa的多变量模型。以临床使用的列线图表示最佳预测模型以图形形式。

研究结果显示，年龄、直肠指检、tPSA、%fPSA、PHI、前列腺体积等多变量模型的准确性最高(AUC: 0.815)。DCA证实了诺模列线图的有效性，与包括年龄、直肠指检和tPSA的基础模型相比，其临床净获益(大于7%)更高。

研究结果表明，基于PHI诺模图是检测侵袭性PCa的有效工具。

原始出处：

L. Foj，X. Filella，Development and internal validation of a novel PHI-nomogram to identify aggressive prostate cancer

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849882, encodeId=67971849882f3, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Aug 24 16:10:05 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366359, encodeId=c2081366359cd, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Mar 21 01:10:05 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463982, encodeId=c613146398253, content=<a href='/topic/show?id=e58691932b6' target=_blank style='color:#2F92EE;'>#诺模图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91932, encryptionId=e58691932b6, topicName=诺模图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13c36558142, createdName=zhangyxzsh, createdTime=Sat Mar 21 01:10:05 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040685, encodeId=d7181040685a3, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Mar 19 13:10:05 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
    2020-08-24 windight

    #CTA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1849882, encodeId=67971849882f3, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Aug 24 16:10:05 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366359, encodeId=c2081366359cd, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Mar 21 01:10:05 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463982, encodeId=c613146398253, content=<a href='/topic/show?id=e58691932b6' target=_blank style='color:#2F92EE;'>#诺模图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91932, encryptionId=e58691932b6, topicName=诺模图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13c36558142, createdName=zhangyxzsh, createdTime=Sat Mar 21 01:10:05 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040685, encodeId=d7181040685a3, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Mar 19 13:10:05 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
    2020-03-21 sunyl07

    #侵袭性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1849882, encodeId=67971849882f3, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Aug 24 16:10:05 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366359, encodeId=c2081366359cd, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Mar 21 01:10:05 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463982, encodeId=c613146398253, content=<a href='/topic/show?id=e58691932b6' target=_blank style='color:#2F92EE;'>#诺模图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91932, encryptionId=e58691932b6, topicName=诺模图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13c36558142, createdName=zhangyxzsh, createdTime=Sat Mar 21 01:10:05 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040685, encodeId=d7181040685a3, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Mar 19 13:10:05 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
    2020-03-21 zhangyxzsh

    #诺模图#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1849882, encodeId=67971849882f3, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Aug 24 16:10:05 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366359, encodeId=c2081366359cd, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Mar 21 01:10:05 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463982, encodeId=c613146398253, content=<a href='/topic/show?id=e58691932b6' target=_blank style='color:#2F92EE;'>#诺模图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91932, encryptionId=e58691932b6, topicName=诺模图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13c36558142, createdName=zhangyxzsh, createdTime=Sat Mar 21 01:10:05 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040685, encodeId=d7181040685a3, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Mar 19 13:10:05 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
    2020-03-19 misszhang

    前列腺癌相关研究，学习了，谢谢梅斯

    0

相关资讯

CLIN CANCER RES：TOP2A和EZH2早期诊断侵袭性前列腺癌

目前的临床参数不能区分出侵袭性前列腺癌。侵袭性前列腺癌是从局部肿瘤进展为远处转移的一种前列腺癌，与大部分前列腺癌相关死亡有关。最近的基因表达研究可以成功预测前列腺癌患者的结局。但是目前尚需能够阻止患者进展为转移性疾病的靶向治疗方法。CLIN CANCER RES近期发表了一篇文章，研究侵袭性前列腺癌的分子标志。

BMJ：多基因风险评分指导侵袭性前列腺癌筛查

多基因危险评分是个体化侵袭性前列腺癌基因风险预测工具，可用于临床风险人群筛查工作的指导